

**Molecular analysis of the helper T cell response in murine interstitial nephritis. T cells recognizing an immunodominant epitope use multiple T cell receptor V beta genes with similarities across CDR3.**

P S Heeger, ... , C J Kelly, E G Neilson

*J Clin Invest.* 1994;**94**(5):2084-2092. <https://doi.org/10.1172/JCI117563>.

**Research Article**

Anti-tubular basement membrane disease (alpha TBM disease) produces T cell-mediated interstitial nephritis in SJL mice after immunization with renal tubular antigen. Initial mononuclear infiltrates appear in vivo after several weeks, with the subsequent progression to renal fibrosis and end stage renal disease over many months. We have analyzed the fine specificity of the autoreactive helper T cell repertoire in alpha TBM disease through the isolation and characterization of a panel of CD4+ Th1 clones harvested after 1-2 wk from animals immunized to produce disease. All clones capable of mediating alpha TBM disease are directed towards a 14-residue immunodominant epitope (STMSAEVPEAASEA) contained within the target antigen, 3M-1. Evaluation of the T cell receptor (TCR) V beta repertoire used by these autoreactive T cells reveals the use of several V beta genes, but with some preference for V beta 14. Sequencing across the putative CDR3 region of the TCR beta chains suggests that common amino acids at the V beta(N)D beta junction and the D beta(N)J beta junction may contribute to the specific ability of these cells to recognize the immunodominant epitope.

**Find the latest version:**

<https://jci.me/117563/pdf>



# Molecular Analysis of the Helper T Cell Response in Murine Interstitial Nephritis

## T Cells Recognizing an Immunodominant Epitope Use Multiple T Cell Receptor V $\beta$ Genes with Similarities across CDR3

Peter S. Heeger,\* William E. Smoyer,\* Theodore Saad,\* Shelley Albert,\* Carolyn J. Kelly,<sup>‡</sup> and Eric G. Neilson\*<sup>§</sup>

\*Penn Center for Molecular Studies of Kidney Diseases, Renal-Electrolyte Division of the Department of Medicine, <sup>§</sup>the Graduate Groups in Immunology and Cell Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104; and the <sup>‡</sup>Division of Nephrology, University of California at San Diego and Veterans Administration Medical Center, San Diego, California 92161

### Abstract

Anti-tubular basement membrane disease ( $\alpha$ TBM disease) produces T cell-mediated interstitial nephritis in SJL mice after immunization with renal tubular antigen. Initial mononuclear infiltrates appear in vivo after several weeks, with the subsequent progression to renal fibrosis and end stage renal disease over many months. We have analyzed the fine specificity of the autoreactive helper T cell repertoire in  $\alpha$ TBM disease through the isolation and characterization of a panel of CD4<sup>+</sup> Th1 clones harvested after 1–2 wk from animals immunized to produce disease. All clones capable of mediating  $\alpha$ TBM disease are directed towards a 14-residue immunodominant epitope (STMSAEVPEAASEA) contained within the target antigen, 3M-1. Evaluation of the T cell receptor (TCR) V $\beta$  repertoire used by these autoreactive T cells reveals the use of several V $\beta$  genes, but with some preference for V $\beta$ 14. Sequencing across the putative CDR3 region of the TCR  $\beta$  chains suggests that common amino acids at the V $\beta$ (N)D $\beta$  junction and the D $\beta$ (N)J $\beta$  junction may contribute to the specific ability of these cells to recognize the immunodominant epitope. (*J. Clin. Invest.* 1994. 94:2084–2092.) Key words: autoimmunity • autoimmune disease • kidney diseases • gene rearrangement •  $\beta$ -chain • T cell antigen receptor

### Introduction

Recent advances in immunology have facilitated the examination of autoimmune T cell repertoires (1–3), and have provided important insights into the molecular basis of autoreactive T cell recognition of target antigenic immunodominant epitopes (3–7). Analyses of T cell receptor (TCR)<sup>1</sup> variable (V) region

genes used by autoreactive T cells in animal models of autoimmunity (3, 8–12) as well as in human autoimmune diseases (3, 13–16), have revealed numerous instances of autoreactive T cell repertoires containing the preferential use of individual V $\beta$  region genes. Such work has resulted in successful, specific anti-V $\beta$  gene immunotherapy (2, 3, 6, 17, 18). Despite these findings, there remains some controversy about the extent of restricted V region gene repertoires in autoimmune diseases (16), especially in systems lacking good information about epitope recognition.

We have been studying the cellular and molecular mechanisms involved in the expression of autoimmune interstitial nephritis (19, 20). In one such model, anti-tubular basement membrane ( $\alpha$ TBM) disease in the SJL mouse, autoimmune interstitial nephritis is induced by immunizing susceptible animals with a rabbit renal tubular antigen preparation in complete Freund's adjuvant (RTA/CFA) (21). Animals develop nonpathogenic anti-tubular basement membrane antibodies in 7–10 d (22), with a subsequent renal mononuclear cell infiltrate at 6–8 wk (21, 22), that progresses to interstitial fibrosis, end stage renal disease, and death (21, 23). The development of  $\alpha$ TBM disease depends upon the emergence of a CD4<sup>+</sup> helper T cell reactive to the target antigen 3M-1 (7), which is expressed on the surface of proximal renal tubular epithelial cells (24). These helper T cells induce the development of 3M-1-reactive CD8<sup>+</sup> effector T cells (25, 26), that mediate cytotoxicity and delayed-type hypersensitivity (DTH), and can adoptively transfer disease to naive syngeneic recipients (26, 27).

To further characterize the helper T cell repertoire in  $\alpha$ TBM disease, we have set out to evaluate the peptide antigen specificity, and the selection of T cell receptor V $\beta$  genes in CD4<sup>+</sup> nephritogenic helper T cells.

### Methods

**Antigens.** Rabbit renal tubular antigen (RTA) was isolated by previously published methods (28), and emulsified at 8 mg/ml with complete Freund's adjuvant (4 mg/ml of purified protein derivative from Connaught Laboratories Ltd, Toronto, Ontario, Canada; mixed with incomplete Freund's adjuvant purchased from GIBCO BRL, Grand Island, NY) to produce RTA/CFA; ~0.2 ml was injected over multiple sites. Soluble renal tubular antigen (SRTA) was made from lyophilized RTA by collagenase digestion (29). Peptides P1 (LLRRRHGDRRSTMSAEV), P2 (ASAEQKEMEDKVTSPKAEAA), and P3 (STMSAEVPEAASAE) were derived from the deduced amino acid sequence of the cloned cDNA for 3M-1 (7, 30) and were synthesized by standard peptide synthetic techniques (31), and HPLC purified (University of Pennsylvania peptide synthesis facility, Philadelphia, PA, and Research Genetics, Huntsville, AL).

**Immunization.** SJL mice (H-2<sup>d</sup>) 4–6 wk of age (Jackson Laboratory,

P. S. Heeger's present address is Cleveland VA Medical Center 111K(W), 10701 East Blvd., Cleveland, OH 44106.

Address correspondence to Eric G. Neilson, M.D., C. Mahlon Kline Professor of Medicine, 700 Clinical Research Building, University of Pennsylvania, 422 Curie Boulevard, Philadelphia, PA 19104-6144.

Received for publication 6 October 1993 and in revised form 23 June 1994.

1. Abbreviations used in this paper:  $\alpha$ TBM, anti-tubular basement membrane; DTH, delayed-type hypersensitivity; RTA, renal tubular antigen; SRTA, soluble RTA; TCR, T cell receptor.

Bar Harbor, ME) were immunized with RTA/CFA in multiple sites to get  $\alpha$ TBM disease (21).

**Isolation and maintenance of T cell lines and clones.** T cell lines were established by standard methods (26, 32). Immune cells harvested from draining lymph nodes of SJL mice 10–14 d after immunization were placed in a 24-well culture plate in 2 ml of complete T cell media containing 20  $\mu$ g/ml of appropriate antigen and cultured at 37°C in 5% CO<sub>2</sub> for 4 d. Complete T cell media consists of RPMI 1640 (JRH Biosciences, Lenexa, KS), supplemented with 10% complement-depleted fetal calf serum, 5% NCTC (Whittaker Bioproducts, Walkersville, MD), 2  $\times 10^{-5}$  M 2-mercaptoethanol, glutamine, and antibiotics. After 4 d, and then weekly thereafter, the cells were harvested and placed in fresh media containing antigen, 20% MLA 144 supernatant as a source of IL-2 and other growth factors (33), and 3–5  $\times 10^6$  irradiated (2,500 rads) syngeneic splenic feeder cells (26). T cell lines were cloned twice by limiting dilution in 96-well plates (26), and then expanded and passaged weekly as described above. Some clones were stimulated weekly with SRTA (M33.25.6, M36.9.1, M36.6.1, and M30.2), while others were stimulated weekly with either the P1 (M34.7.3, M34.4.3, M31.1, M31B.3.3) or P2 (M35.2.7, M32.18.2.2) peptide, alone.

**Cytokine transcript production by T cell clones.** T cell clones were harvested at the end of a 7 d cycle, and were isolated from any remaining dead splenocytes with Lympholyte-M™ (Cedar Lane Laboratories, Ltd., Hornsby, Ontario, Canada) as per manufacturer recommendations. 2–4  $\times 10^6$  T cells were then cultured in 2 ml of T cell media in 24 well plates, with Concanavalin A (Con A) at 5  $\mu$ g/ml, for 6 h. The supernatants were stored at –20°C for use in HT-2 cell assays, and the cells were washed with T cell media and pelleted. Total RNA was made from the T cells (as well as from snap frozen SJL mouse spleen) by the guanidinium isothiocyanate isolation procedure (34). First strand cDNA was made with mMLV (GIBCO BRL) and oligo-dT (34, 35). 500 ng of the resultant RNA/cDNA was used in a 100  $\lambda$  polymerase chain reaction, containing 10  $\lambda$  of 10 $\times$  buffer (Perkin-Elmer Cetus, Exton, PA) 200  $\mu$ M dGTP, dCTP, dATP, dTTP, 0.25  $\lambda$  Taq polymerase (Perkin-Elmer Cetus) and 40 pmol of each oligonucleotide primer. Primer sequences were derived from the cDNAs found in Genbank for IL-2, IL-4, and  $\gamma$ IFN. All oligonucleotide primers were synthesized on an Applied Biosystems 391 DNA Synthesizer (Foster City, CA) and purified with an oligonucleotide purification cartridge as per manufacturer's recommendations. The sequences are as follows: IL-2 sense, 5'CCACTTCAAGCTCTACAGCCGG3'; IL-2 antisense, 5'CCTTATGTGTTGTAAGCAGGAGG3'; IL-4 sense, 5'GCTTCTCTAACAGTAGAAACC3'; IL-4 antisense, 5'CCGACAGCGAGACCCAAATCTGTC3';  $\gamma$ IFN sense, 5'GGTCAGTGAAGTAAAGGTACAAGC3';  $\gamma$ IFN antisense, 5'GGAAGAGATTGTCCCAATAAGAA-TA3'. Predicted product sizes are:  $\gamma$ IFN, 308 bp; IL-2, 463 bp; and IL-4, 302 bp. cDNA amplification was performed in a Perkin-Elmer Cetus DNA thermal cycler (Perkin-Elmer Cetus) for 35 cycles at 92°C denature for 30 s, 52°C anneal for 60 s, and 72°C elongation for 120 s. 15% of the resultant products were run out on a 2% agarose gel and photographed.

**HT-2 proliferation assay.** HT-2 cells (kindly provided by Michael Madaio, University of Pennsylvania) were maintained with twice weekly passage in T cell media supplemented with 2 U/ml murine recombinant IL-2 (Boehringer Mannheim Biologicals, Indianapolis, IN). Before use, the cells were pelleted, washed in fresh T cell media, and rested for 3 h at 37°C in 5% CO<sub>2</sub>. 20,000 rested HT-2 cells were incubated with 100  $\lambda$  of T cell clone supernatant and 1  $\mu$ Ci [<sup>3</sup>H]-thymidine (Amersham Corp., Arlington Heights, IL) in a total of 200  $\lambda$ , in 96-well culture plates for 16–48 h. In some experiments, anti-IL-2 blocking antibody (36) (kindly provided by Dr. Glen Gaulton, Department of Pathology, University of Pennsylvania), or murine polyclonal IgM (Bionetics, Charleston, SC), was added at 4  $\mu$ g/ml. Cells were harvested and counted, and the results expressed as the mean of three experiments  $\pm$  SEM.

**Cytofluorography.** Splenic lymphocytes or T cell clones (at the end of a 7-d passage) were purified through Lympholyte-M™ and washed

with phosphate buffered saline (PBS) with 0.1% BSA. 1–2  $\times 10^6$  cells were suspended in 50  $\lambda$  of PBS/0.1% BSA and incubated with a 1:50 dilution of FITC-conjugated antibody for 30 min on ice. Specific FITC-conjugated antibodies for CD4, CD8 (37), TcR $\alpha\beta$  (38), TcR V $\beta$ 7 (39), TcR V $\beta$ 3 (40), TcR V $\beta$ 14 (41), were purchased from Pharmingen (San Diego, CA). PE-conjugated  $\alpha$ CD4 antibody was kindly provided by Bruce Freedman, M. D. (Dept. of Pathology, University of Pennsylvania, Philadelphia, PA). FITC-conjugated goat anti-rabbit antibody was obtained from Boehringer Mannheim Biologicals. The cells were washed three times in PBS/0.1% BSA, and resuspended in 2% paraformaldehyde/PBS. Fluorescence was recorded on a FACScan® cytofluorograph (24, 42), and analyzed with Lysis II software (Becton Dickinson and Co., San Jose, CA). 10,000 live gated cells were analyzed in each run.

**Lymphocyte blast transformation assay.** T cell clones were harvested at the end of a 7-d passage cycle, purified through Lympholyte-M™, and rested in complete T cell media for 4 h at 37°C in 5% CO<sub>2</sub> (24). 5  $\times 10^6$  T cells were mixed with 3  $\times 10^6$  irradiated syngeneic splenocytes and antigen in a total of 1 ml of T cell media, in a 24-well flat bottom plate, and cultured for 72 h at 37°C in 5% CO<sub>2</sub>. 100- $\mu$ l aliquots were removed and placed in flat bottom 96-well plates, mixed with 1  $\mu$ Ci [<sup>3</sup>H]thymidine (Amersham Corp.) and incubated for an additional 24 h. The cells were harvested and counted and the results expressed as the mean of three experiments  $\pm$  SEM.

**Effector cell induction assay.** The assay was performed as previously described (25, 26, 43). Briefly, 30–250  $\times 10^6$  nonirradiated syngeneic splenocytes were incubated with 20% MLA supernatant, 20  $\mu$ g/ml of antigen, and 20% T cell clone supernatant (taken from the end of a 7-d culture) in a T25 or T75 culture flask (Falcon; Becton Dickinson Labware, Lincoln Park, NJ) for 5 d at 37°C in 5% CO<sub>2</sub>. At the end of the culture period, the induced effector T cells were washed extensively in standard media followed by PBS, and were used for local adoptive transfer of delayed-type hypersensitivity (DTH) or subcapsular transfer.

**Local adoptive transfer of DTH.** This assay has been previously reported in detail (25, 26). Induced effector cells, as described above, were resuspended in PBS at 2.0  $\times 10^7$  cells/ml, with or without antigen (10  $\mu$ g/ml), and 25  $\lambda$  of each cell preparation was injected into the hind footpads of recipient naive SJL mice (three per group). Footpad swelling as an index of DTH was measured 48 h later using a spring-loaded engineer's micrometer (Schlesingers for Tools, Brooklyn, NY). The magnitude of swelling was expressed as the mean increment between the antigen-challenged footpad and that injected with PBS in inches  $\times 10^{-3} \pm$  SEM. All measurements were performed by an individual blinded to the experimental protocol.

**Subcapsular transfer experiments.** Naive syngeneic mice were anesthetized and 10<sup>8</sup> induced effector lymphocytes (derived from an effector cell induction as described above) in 75  $\lambda$  of PBS were injected under the kidney capsule with a 30-gauge needle. After 7 d, the kidneys were harvested, fixed in 10% buffered formalin, and stained with hematoxylin and eosin. The stained sections were interpreted by an investigator blinded to the experiment (25, 43).

**TCR V $\beta$  gene analysis by cDNA amplification.** Total RNA was prepared from Lympholyte-M™-treated T cell clones or snap frozen whole spleen by the guanidinium isothiocyanate method (34). Oligo dT-primed first-strand synthesis was performed with mMLV reverse transcriptase (34, 35). PCR was performed in 100  $\lambda$  total volume, as described above, using 750 ng of RNA/cDNA template, 40 pmol of 3' antisense primer PH12 (C $\beta$ ; 5'CTCAAACAAGGAGACCTTG3') and 40 pmol of 5' sense V $\beta$  region primer. The 5' V $\beta$  amplification primers for V $\beta$ 1-V $\beta$ 19 were derived by William Smoyer and Carolyn Kelly (University of Pennsylvania, Philadelphia, PA and University of California, San Diego, CA) using a matrix analysis (Macvector sequence analysis software for the Macintosh, IBI, New Haven, CT) and the published murine V $\beta$  gene sequences (44–46) (manuscript in preparation). Each primer is a 20 mer designed to have minimal cross-reactivity to all other V $\beta$  region genes and encodes a product of unique predicted size. The V $\beta$ 20 primer was designed later from the published sequence (47) using the same criteria, and has the following sequence: 5'GCAGTTACA-

CAGAAGCCAAG3'. Predicted sizes for PCR products using the 3' PH12 primer (C $\beta$ ) and each of the 5' V $\beta$  primers are as follows: V $\beta$ 1,387 bp; V $\beta$ 2,256 bp; V $\beta$ 3,250 bp; V $\beta$ 4,213 bp; V $\beta$ 6,373 bp; V $\beta$ 7,165 bp; V $\beta$ 10,355 bp; V $\beta$ 14,253 bp; V $\beta$ 15,394 bp; V $\beta$ 16,234 bp; V $\beta$ 17,319 bp; V $\beta$ 18,327 bp; V $\beta$ 19,312 bp; and V $\beta$ 20,376 bp. The actual sizes of each product may vary by several base pairs secondary to N region additions and deletions. A master mix of all reagents except the 5' primers was made and divided into 14 tubes each containing one specific V $\beta$  region primer. A fifteenth control tube was run containing two constant region primers 5'-C $\beta$  (5'TACCCTTGCTGCTTGGC-CA3') and WAS-2 (5'GAACTGCACTTGGCAGCGA3'), encoding a predicted product of 207 bp. Amplifications were performed in a DNA thermal cycler (Perkin-Elmer Cetus) for 35 cycles at 92°C denature for 30 s, 54°C anneal for 60 s, and 72°C elongation for 120 s. 15% of each reaction was run on a 2% agarose gel and photographed (34, 48).

A cDNA product encoding the T cell receptor V $\beta$  region from one of the T cell clones was also obtained using anchored PCR (35). Briefly, first strand synthesis was performed using mMLV and a specific 3' TcR C $\beta$  antisense primer C $\beta$ dan, 5'TCAGGAATTCCTTTTGA3' (49). The cDNA was then G tailed, and amplifications were performed using an internal 3' primer, PH12, and a 5' poly C primer (35).


**Southern hybridization.** PCR products were transferred to a Zetabind (Cuno, Inc., Meriden, CT) membrane by capillary action using standard techniques, denatured for 10 min with 0.4 M NaOH, and UV cross-linked (Stratalinker; Stratagene, La Jolla, CA). Prehybridization and hybridization were performed as previously described (34) using 1  $\times$  10<sup>6</sup> counts per ml of a <sup>32</sup>P- $\gamma$ -ATP-labeled (34) internal C $\beta$  primer, PH15 (5'GAGTCACATTTCTCAGATC3'). The blot was washed twice in 6  $\times$  SSC at 4°C for 20 min, and then washed twice in 3 M tetramethylammonium chloride (Aldrich Chemical Co., Inc, Milwaukee, WI), 50 mM Tris HCl, pH 8.0, 2 mM EDTA, and 0.1% SDS at 55°C for 30 min, then autoradiographed.

**Cloning and sequencing of the V $\beta$  PCR products.** V $\beta$  PCR products were cloned into the TA cloning system (Invitrogen, La Jolla, CA). DNA was prepared for sequencing using the dideoxy chain termination (34, 35). Most V $\beta$  genes, including the product isolated by anchored PCR, were subcloned from two different PCR reactions, and a single colony from each of the ligations was sequenced, in order to minimize any potential Taq polymerase-induced errors. Sequence analysis was done using the Macvector™ sequence analysis program for the Macintosh (IBI). For the isolation of the cDNA for the TcR $\beta$  chain of clone M30.2, we screened an M30.2 cDNA library in Lambda Zap II with a 530-bp TcR C $\beta$  probe (inserted in a PstI site of PBR322) kindly provided by Dr. Mark Greene (Department of Pathology, University of Pennsylvania). A full length cDNA clone was obtained, and sequenced as well.

**Sequence comparison of T cell receptor deduced amino acid sequences.** 52 random murine TcR $\beta$  junctional sequences were obtained from the October 15, 1993 Entrez:Sequences program (NCBI, Bethesda, MD) using the keywords "T-cell receptor" and "T-cell receptor beta." Only sequences encoding functional TcRs in which the V $\beta$ /D $\beta$  and D $\beta$ /J $\beta$  junctions were identified were analyzed. Statistical comparisons were done using  $\chi^2$  analysis.

## Results

**Selection of potential antigenic peptides.** Two potential antigenic epitopes, P1 and P2 were chosen from the deduced amino acid sequence of the cloned cDNA for the target antigen of  $\alpha$ TBM disease, 3M-1 (7), using a software algorithm integrating a variety of determinants of protein conformation to assist in the prediction of peptide immunogenicity (50) (Fig. 1). P1 is an 18-amino acid peptide, separated by two amino acids from the 22-residue peptide, P2. We later chose a third, overlapping candidate 14 residue peptide, P3 (Fig. 1), that starts at a potential Cathepsin B site (after Arg-Arg), because Cathepsin B



**Figure 1.** Amino acid sequences of the potential antigenic epitopes P1, P2, and P3. Abbreviations are the standard single letter amino acid codes. The eight residues in bold type represent the core amino acids of the immunodominant epitope recognized by the nephritogenic T cell clones.

has been shown to be relevant in processing of other antigens presented in the context of MHC class II molecules (51).

**General characterization of the T cell clones.** To evaluate the relevance of peptides P1, P2, and P3 to the T helper cell response in  $\alpha$ TBM disease, we prepared T cell clones from the draining lymph nodes of several SJL/J animals immunized to get  $\alpha$ TBM disease. The T cell clones were stimulated weekly with either P1, P2, or SRTA. 10 clones were isolated from 8 different animals: 4 were stimulated with SRTA (M33.25.6, M36.9.1., M36.6.1, and M30.2), 4 were stimulated weekly with P1 (M34.7.3, M34.4.3, M31.1, and M31B.3.3), and 2 were stimulated weekly with P2 (M35.2.7, M32.18.2.2).

Previous work by our laboratory has shown that CD4<sup>+</sup> T cells overgrow all other T cell subtypes when isolated by our methods (26). The CD4<sup>+</sup>, CD8<sup>-</sup>, TcR  $\alpha\beta$ <sup>+</sup> phenotype of each T cell clone was confirmed with FACS analysis using specific FITC-conjugated antibodies. A representative analysis of one clone is shown in Fig. 2. All of the isolated T cell clones expressed this identical phenotype.

**Cytokine expression profile of T cell clones.** The reverse transcription polymerase chain reaction (RT-PCR) was initially used to analyze the cytokine profile of each T cell clone. Pilot studies were done using total spleen RNA to determine optimal parameters for the detection of each transcript, and to show that amplification was in the linear range without evidence of plateau (data not shown). The cytokine profile of two representative T cell clones is shown in Fig. 3 A, and reveals appropriate sized products for  $\gamma$ IFN and IL-2, but not IL-4, while all three transcripts are found in splenic RNA. All of the clones exhibited the same cytokine transcript profile. Confirmation of IL-2 production by selected Con A stimulated T cell clones is shown in Fig. 3 B. Supernatants induced proliferation of HT-2 cells that was almost completely blocked by anti-IL-2 antibody, but was unaffected by a polyclonal, control, isotype matched, mouse IgM. All clones tested behaved in a similar fashion (data not shown).

**Antigen specificity as determined by local adoptive transfer of DTH.** We initially chose to determine the antigen specificity of each clone using a functional assay, the ability to induce an antigen-specific, DTH-producing effector cell population. Each clone was tested with SRTA, P1, P2, and P3. As can be seen in Table I, the four clones stimulated weekly with SRTA (M26.9.1, M33.25.6, M30.2, M36.6.1) were able to induce an antigen-specific DTH response with SRTA, P1 and P3, but not with P2. Similarly, the four clones stimulated weekly with P1 (M34.7.3, M34.4.3, M31B.3.3, M31.1) had the same specificity for SRTA, P1, and P3, but not P2 (Table I). Notably, all eight clones reactive to SRTA were also reactive to P3, implying that P1/P3 is the sole antigenic epitope within the 3M-1 protein in




Figure 2. FACS analysis of clone M36.9.1 using FITC-conjugated antibodies to CD4 (upper right panel), CD8 (lower left panel), and TcR  $\alpha\beta$  (lower right panel). A FITC-conjugated goat anti-rabbit antibody served as a negative control (upper left panel).

the SJL mouse. The two clones stimulated weekly with P2, however, were only able to induce a DTH response with P2, and not to the intact antigen, SRTA, or to the peptides P1 and P3 (Table I).

*Antigen specificity as determined by lymphocyte proliferation assay.* Selected T cell clones were additionally tested for their ability to proliferate specifically to the peptide antigens in a standard lymphocyte proliferation assay. As can be seen in

Fig. 4, clone M36.9.1 and M33.25.6 proliferate to peptides P1 and P3, but not to P2, consistent with our DTH results.

*Subcapsular transfer of induced effector cells.* Previous work has shown that the M30.2 clone (SRTA, P1 and P3-reactive) can induce effector cells that cause renal interstitial injury within 5 d of renal subcapsular transfer (7, 43). We next wished to test this finding on other P3-reactive clones and to evaluate whether P2-reactive clones could mediate renal inter-




Figure 3. Cytokine profile of selected T cell clones. (A) Representative PCR results for  $\gamma$ IFN (308 bp), IL-2 (463 bp), and IL-4 (304 bp) from total spleen RNA (left), clone M36.9.1 RNA (middle), and clone M35.2.7 RNA (right). Phi is a nucleotide marker. (B) HT-2 cell proliferation assay. ( $\square$ ) Media alone; ( $\blacksquare$ ) rIL-2 at 0.2 U/ml; ( $\blacksquare$ ) supernatants from Con A-stimulated T cell clone M36.9.1; ( $\blacksquare$ ) supernatants from Con A-stimulated T cell clone M35.2.7. Experiments with rIL-2 and the T cell clone supernatants were performed with no additives (none), antiIL-2 antibody at 4  $\mu$ g/ml (anti-IL-2), or a control polyclonal IgM at 4  $\mu$ g/ml (IgM).  $n = 3$  in each experiment;  $P < 0.05$  between anti-IL-2 effect and the IgM control.

Table 1. Antigen Specificity of T Cell Clones by DTH

Clone	Weekly stimulus	DTH			
		SRTA	P1	P2	P3
M30.2	SRTA	18.7±2.1	19.3±1.2	3.0±2.0	18.3±3.1
M33.25.6	SRTA	18.3±1.5	18.6±5.5	3.0±0.0	17.0±0.0
M36.6.1	SRTA	16.3±0.6	19.3±0.6	3.7±1.2	16.7±1.5
M36.9.1	SRTA	19.3±1.2	17.7±1.2	4.7±0.6	17.0±2.6
M34.4.3	P1	19.3±1.2	19.0±0.3	3.0±1.0	17.3±2.5
M34.7.3	P1	19.0±2.6	16.7±0.3	3.7±0.6	21±1.7
M31.1	P1	16.0±1.7	17.7±1.5	3.0±1.4	17.5±0.7
M31B.3.3	P1	18.0±1.0	20.0±1.0	3.3±1.2	18.0±1.7
M32.18.2	P2	3.3±1.2	2.3±2.1	18.0±3.1	3.7±2.5
M35.2.7	P2	3.3±1.2	3.7±0.9	15.3±1.0	3.0±1.7

stitial injury. Fig. 5 shows that clone M34.4.3 (P3 reactive) can mediate acute renal injury when P1 peptide is used in the effector cell induction culture (Fig. 5 A). A significant renal infiltrate with tubular degeneration and atrophy occurred within 5 d of subcapsular injection of M34.4.3/P1-induced effector cells (Fig. 5 A). The same clone was unable to cause renal injury when P2 was used in the induction culture (not shown), confirming the antigen specificity of this phenomenon. Similar interstitial renal injury was produced by all eight P3-reactive clones when the P3 peptide was used in the induction culture (data not shown). In contrast, a P2 reactive clone (M35.2.7) was unable to induce nephritogenic effector cells when either P1 (not shown) or P2 (Fig. 5 B) was used in the induction cultures. In these kidneys, we were able to find injected lymphocytes under the capsule of the kidneys, but the histology was indistinguishable from normal controls.

**Analysis of TcR Vβ gene usage by nephitogenic helper T cell clones.** We next wished to evaluate the TcR Vβ gene used by individual P3-reactive T cell clones. Specificity of the Vβ PCR primers was first demonstrated by Southern analysis of Vβ cDNA amplifications from total spleen RNA using an inter-




Figure 4. Lymphocyte blast transformation assay of selected T cell clones. (■) Clone M36.9.1; (■) clone M33.25.6. Peptide antigens P1, P2, or P3 were added at 50 μg/ml. n = 3 for each group.




Figure 5. Subcapsular transfer of induced effector lymphocytes. (A) Effector cells induced with M34.4.3 (P1- and P3-reactive) and P1 peptide transfer florid interstitial nephritis with a mononuclear cell infiltrate, tubular degeneration and atrophy. (B) Effector cells induced with M35.2.7 (P2-reactive) and P2 peptide are not capable of transferring disease.

nal Cβ region primer, PH15 (Fig. 6). All Vβ PCR products were of predicted size and bound specifically to the internal primer. The genes encoding Vβ5, Vβ8, Vβ9, Vβ11, Vβ12, and Vβ13 are deleted from the genome of SJL mice (52), and were therefore not analyzed.

Fig. 7 shows the results of the TcR Vβ analysis for two representative P3-reactive T cell clones. RT-PCR for TcR Vβ genes performed on RNA from clone M31.1 reveals a product for Vβ14 and a Cβ control (Fig. 7 A, left). Surface expression of Vβ14 was confirmed by FACS (Fig. 7 A, right). Similarly, clone M36.9.1 expresses Vβ7 (Fig. 7 B). The Vβ genes used by all 10 T cell clones are shown in Fig. 8. The Vβ genes expressed by six of the clones (those expressing Vβ3, 7, and 14) were confirmed by FACS. No antibodies for Vβ1, 10, 15, and 16 were available. Six Vβ genes were used by the eight different P3-reactive T cell clones, with three clones, M33.25.6, M31.1, and M31B.3., using Vβ14. The two P2-reactive clones used Vβ7 and Vβ1 (Fig. 8). To assess the baseline frequency of Vβ3, Vβ7, and Vβ14 within the peripheral T cell repertoire of the SJL mouse, we performed FACS analysis on freshly isolated splenic lymphocytes derived from unimmunized animals. Double labeling experiments using a PE-conjugated αCD4 antibody, and FITC-conjugated αVβ antibodies revealed that Vβ3, Vβ7, and Vβ14 make up 5%, 5%, and 6.5% of the CD4+ T cell population, respectively (data not shown).

**Analysis of the Vβ/Dβ/Jβ junctional sequences.** The individual Vβ PCR products were then cloned into the PCR 3000 vector (Invitrogen), sequenced, and compared with the known




Figure 6. Southern blot of Vβ PCR products from splenic RNA probed with an internal Cβ oligonucleotide, PH15. Predicted product sizes are listed in Methods.




Figure 7. T cell receptor V $\beta$  expression by individual T cell clones. (A) RT-PCR for V $\beta$  genes using RNA from clone M31.1 revealing a PCR product for V $\beta$ 14 (253 bp) and for C $\beta$  (207 bp), with confirmatory surface expression by FACS using a specific V $\beta$ 14 antibody. (B) RT-PCR for V $\beta$  genes using RNA from clone M36.9.1 revealing a PCR product for V $\beta$ 7 (165 bp) and for C $\beta$  (207 bp), with confirmatory surface expression by FACS using a specific V $\beta$ 7 antibody. An FITC conjugated goat anti-rabbit antibody served as a negative control for the FACS studies.

V $\beta$  (44–46), D $\beta$  (53), and J $\beta$  (54, 55) gene sequences. In all cases, the sequence of the V $\beta$  PCR product corresponded to the known nucleotide sequence of that particular V $\beta$  gene, further confirming the specificity of the cDNA amplification products. The nucleotide sequences, D gene, J gene, and deduced amino acid sequences of the 10 T cell clones are shown in Fig. 8. An appropriate open reading frame was present from the V region, through the VDJ junction and into the constant region of the T cell receptor in each case. The eight P3-reactive clones use five

different J $\beta$  genes, with a preponderance of J $\beta$  1.2 (used by M33.25.6, M31.1, M31B.3.3, and M36.9.1). Six of the eight P3-reactive clones use D $\beta$ 1.1.

The deduced amino acid sequences of the TcR $\beta$  chains from the eight P3-reactive T cell clones are remarkably similar across the V $\beta$ /D $\beta$ /J $\beta$  junction, with clones M33.25.6, M31.1, M31B.3, and M30.2 showing identical or conservatively substituted amino acids in 5 or 6 positions. All eight P3-reactive clones have a small nonpolar amino acid (Ala, Val, Leu, or Gly) at the D $\beta$ /J $\beta$  junction (residue 102 or 103), and five of the eight clones have a cationic, basic residue (Arg or Lys) at the V $\beta$ /D $\beta$  junction (residue 100). Residues in both of these positions are encoded primarily by N region deletions or additions (underlined in Fig. 8), and are thus potentially highly variable. Five of the eight P3-reactive clones additionally have an Asn residue 104. In the lower portion of Fig. 8 are the deduced amino acid sequences of the TcR  $\beta$  chains from the two, P2-reactive clones. The sequence of the V $\beta$ /D $\beta$ /J $\beta$  junctions shows some homology to the P3-reactive clones, but position 103 contains a charged residue (Arg in M32.18.2 and Glu in M35.2.7) as opposed to a small nonpolar residue. Additionally, position 100 is Tyr or His in the P2 reactive clones, and not Arg as found in most of the P3-reactive clones.

To confirm the relevance of the sequence findings, we analyzed a random sample of 52 V $\beta$ /D $\beta$ /J $\beta$  sequences for the presence of Ala, Val, Leu or Gly residue at the D $\beta$ /J $\beta$  junction, or an Arg or Lys at the V $\beta$ /D $\beta$  junction. 14 of 52 sequences contained an Ala, Val, Leu, or Gly at the D $\beta$ /J $\beta$  junction, compared to 8/8 of our P3 reactive clones ( $P < 0.001$ ), while 14/52 of the random sequences contained an Arg or Lys at the V $\beta$ /D $\beta$  junction, compared to 5/8 of our P3-reactive clones ( $P < 0.05$ ). Additionally, 6/8 of the P3-reactive V $\beta$ /D $\beta$ /J $\beta$  sequences are cationic (with the other two having an overall neutral charge), compared with the 5/52 incidence found in the randomly chosen T cell sequences ( $P < 0.001$ ).

#### V $\beta$ /D $\beta$ /J $\beta$ Junctional Sequences

Clone	95	96	97	98	99	100	101	102	103	104	105	106	Peptide Specificity				
M33.25.6	<b>V<math>\beta</math>14</b>				<b>D<math>\beta</math>1.1</b>				<b>J<math>\beta</math>1.2</b>				P3				
	TGT	GCC	TGG	AGT	C	G	A	G	G	A	A	A		AAC	TCC	GAC	
	Cys	Ala	Trp	Ser	Arg	Gln	Gly	Ala	Asn	Ser	Asp						
M31.1	<b>V<math>\beta</math>14</b>				<b>D<math>\beta</math>1.1</b>				<b>J<math>\beta</math>1.2</b>				P3				
	TGT	GCC	TGG	AGT	A	A	A	G	G	A	A	A		AAC	TCC	GAC	
	Cys	Ala	Trp	Ser	Lys	Gln	Gly	Ala	Asn	Ser	Asp						
M31B.3.3	<b>V<math>\beta</math>14</b>				<b>D<math>\beta</math>1.1</b>				<b>J<math>\beta</math>1.2</b>				P3				
	TGT	GCC	TGG	AGT	C	T	A	G	G	G	G	A		AAC	TCC	GAC	
	Cys	Ala	Trp	Ser	Leu	Gln	Gly	Ala	Asn	Ser	Asp						
M30.2	<b>V<math>\beta</math>3</b>				<b>D<math>\beta</math>1.1</b>				<b>J<math>\beta</math>1.4</b>				P3				
	TGT	GCC	AGC	AGT	C	A	G	G	G	G	C	T		AAC	GAA	AGA	
	Cys	Ala	Ser	Ser	Gln	Gly	Val		Asn	Glu	Arg						
M36.9.1	<b>V<math>\beta</math>7</b>				<b>D<math>\beta</math>1.1</b>				<b>J<math>\beta</math>1.2</b>				P3				
	TGT	GCT	AGC	AGC	C	G	A	G	G	G	C	A		AAC	TCC	GAC	
	Cys	Ala	Ser	Ser	Arg	Arg	Gly		Asn	Ser	Asp						
M36.6.1	<b>V<math>\beta</math>10</b>				<b>D<math>\beta</math>1.1</b>				<b>J<math>\beta</math>2.5</b>				P3				
	TGT	GCC	AGC		A	G	G	A	G	A	G	C		GAA	GAC	ACC	
	Cys	Ala	Ser		Arg	Glu	Gly	Leu	Glu	Asp	Thr						
M34.9.9	<b>V<math>\beta</math>15</b>				<b>D<math>\beta</math>2.1</b>				<b>J<math>\beta</math>2.4</b>				P3				
	TGT	GGT	GCT	ACG					G	G	G	G		CAC	ACC		
	Cys	Gly	Ala	Thr					Gly	Gly				His	Thr		
M34.4.3	<b>V<math>\beta</math>16</b>				<b>D<math>\beta</math>2.1</b>				<b>J<math>\beta</math>2.3</b>				P3				
	TGT	GCC	AGC	AGC	C	C	C	C	A	G	G	G		C	C	CAA	ACG
	Cys	Ala	Ser	Ser	Pro	Arg	Leu	Gly	Gly	Arg	Gln	Thr					
M32.18.2	<b>V<math>\beta</math>1</b>				<b>D<math>\beta</math>1.1</b>				<b>J<math>\beta</math>2.5</b>				P2				
	GCC	AGC	AGC	C	T	C	T	A	C	A	G	G		AGG	CAA	GAC	
	Ala	Ser	Ser	Leu	Tyr	Arg	Gly	Arg	Arg	Gln	Asp						
M35.2.7	<b>V<math>\beta</math>7</b>				<b>D<math>\beta</math>1.1</b>				<b>J<math>\beta</math>1.1</b>				P2				
	GCT	AGC	AGT		C	A	C	A	G	G	G	A		GAA	GTC	TTC	
	Ala	Ser	Ser		His	Arg	Gly	Thr						Glu	Val	Phe	

Figure 8. Aligned nucleotide and deduced amino acid sequences of the ten T cell clones across the V $\beta$ /D $\beta$ /J $\beta$  junction. The V $\beta$ , D $\beta$ , and J $\beta$  genes used by each clone are in bold type above each sequence. Underlined nucleotides represent positions of N region additions/deletions. Amino acid residue numbers 95–106 are listed across the top of the figure.

## Discussion

We have successfully isolated a panel of CD4<sup>+</sup>, TcR  $\alpha\beta$ -expressing T cell clones from mice immunized to get  $\alpha$ TBM disease. The cytokine profiles and the functional characteristics (i.e., the ability to provide T cell help for the induction of DTH-

producing effector cells) of these clones are consistent with a Th1 phenotype (56). We have not tested these clones for their ability to induce a humoral immune response, however, and cannot fully exclude B cell help as a potential function of these cells. Additionally, we have not yet attempted to preferentially isolate Th2-like cells from these animals.

Antigen specificity was demonstrated functionally in all clones by an established biological assay (25, 43), and confirmed in selected clones through the use of a proliferation assay (24, 26). All clones stimulated weekly with SRTA or P1 specifically reacted to the P3 peptide, and not to P2, suggesting that these T cell clones recognize a core sequence of eight amino acids (STMSAEVP, bold letters in Fig. 1). Interestingly, this core sequence, as well as the entire P3 epitope, is anionic, and contains no positively charged residues (Fig. 1). Future work involving the elution of peptide from MHC II molecules (57), and a systematic evaluation of T cell reactivity to overlapping and mutated peptides, will be required to potentially identify the optimal peptide size, and the importance of individual residues in the recognition of this immunodominant epitope by the different T cell clones.

We also isolated two CD4<sup>+</sup> Th1 T cell clones which recognized the P2 peptide in vitro, but were unable to recognize the intact SRTA from which this peptide was derived. We find it curious that these T cell clones, isolated from animals immunized with RTA, can recognize the P2 peptide, but not the intact antigen. Although the explanation for this phenomenon is not readily apparent, the relative difficulty in isolating these clones (we were only able to isolate two) suggests that the target antigen of  $\alpha$ TBM disease, 3M-1, is only rarely processed into P2 (or a peptide containing a significant portion of P2) by I-A<sup>s</sup> antigen presenting cells in the SJL mouse.

The relevance of P3 (but not to P2) to the development of  $\alpha$ TBM disease was demonstrated through showing that the clones reactive to P3 were able to transfer disease to naive recipients, while a P2-reactive clone was not. In sum, these findings suggest that CD4<sup>+</sup>, Th1 helper T cells derived from the peripheral lymphoid system of animals immunized to produce  $\alpha$ TBM disease, and directed towards an immunodominant epitope contained within the P3 peptide, are nephritogenic. Interestingly, both the  $\alpha$ TBM antibody response and the CD8<sup>+</sup> effector T cell response are also directed at P1 (7, 27) (reactivity towards P3 has not been tested), confirming the importance of this antigenic epitope in the pathogenesis of  $\alpha$ TBM disease. Although our results demonstrate a single immunodominant peptide epitope relevant to the development of disease, it is possible that other, secondary, cryptic epitopes emerge within the kidney as the disease process progresses (58). Studies evaluating the peptide specificity of nephritogenic T cells derived from diseased organs will be required to address this issue.

Analysis of the TcR V $\beta$  genes used by the P3 epitope-specific T cell clones revealed the use of several V $\beta$  genes, with a recurrent use (3/8) of V $\beta$ 14. This 38% incidence of V $\beta$ 14 expression by P3-reactive clones, compared with 6.5% of the peripheral CD4<sup>+</sup> T cell population, provides evidence for the preferential use of the V $\beta$ 14 gene by the nephritogenic T cell clones. Collectively, our findings suggest that the anti-3M-1 TCR repertoire is oligoclonal. Whether these findings are representative of the TcR repertoire within diseased organs is an area of ongoing investigation. It should be noted however, that interpretation of TCR gene usage analyses in diseased whole organs is often hampered by the lack of definition of

peptide specificity (16), and results may not correlate with findings derived from peptide specific T cell clones (16).

Perhaps more intriguing than the oligoclonality of the TCR response is the similarity of the deduced amino acid sequences across the V $\beta$ /D $\beta$ /J $\beta$  junction. Based initially on comparative analyses between immunoglobulin and TcR sequences (59, 60), and later confirmed by statistical (61), and mutational (62–64) analyses, the V $\beta$ /D $\beta$ /J $\beta$  junction of the TcR in CD4<sup>+</sup> cells has been proposed to constitute the putative CDR3 region, and thus make direct contact with its peptide/MHC class II ligand. The statistically significant overrepresentation (compared with a random set of functional TcR $\beta$  chains) of a small nonpolar amino acid at the D $\beta$ /J $\beta$  junction, and an Arg or Lys at the V $\beta$ /D $\beta$  junction, both determined by N region additions or deletions, suggests that these residues may be important in the specific recognition of P3. Additionally, the CDR3 region of all of the P3-reactive clones is neutral or cationic (Arg/Lys), with a distinct lack of negative charges (Glu in position 101 of M36.6.1 is the only one, and is counteracted by an adjacent Arg, Fig. 8), suggesting a direct interaction with the anionic P3 peptide. Analogous findings have been noted in another model of autoimmune renal injury (8). The precise determination of the role played by individual residues within the CDR3 in the specific recognition of the P3/MHC class II complex will require a mutational analysis of the TCR. Finally, the sequence of the TCR  $\alpha$  chain needs to be defined before any definitive statements regarding the molecular basis of P3 recognition by autoreactive T cells can be made. Based on these experiments, however, it may be possible to direct specific immunotherapy at a common epitope within the TCR $\beta$  CDR3 region of nephritogenic, P3-reactive T cells.

## Acknowledgments

The authors would like to thank Hank Pletcher for his assistance with the FACS analysis.

This work was supported, in part, by grants for the National Institutes of Health (DK-30280, DK-07006, DK-45191, DK-41110, DK-46282, DK-08446, and DK-42155). P. Heeger is a recipient of a Clinical Investigator Award (K08 DK02125-01) from the National Institutes of Health. W. Smoyer is a recipient of a National Research Service Award (1 F32 DK08607-01) from the National Institutes of Health. S. Albert was supported by the Medical Research Council of Canada.

## References

1. Sinha, A. A., M. T. Lopez, and H. O. McDevitt. 1990. Autoimmune diseases: the failure of self tolerance. *Science (Wash. DC)*. 248:1380–1387.
2. Wraith, D., M. Ho, L. Steinman, and H. Acha-Orbea. 1989. T cell recognition as the target for immune intervention in autoimmune disease. *Cell*. 57:709–715.
3. Acha-Orbea, H., L. Steinman, and H. O. McDevitt. 1989. T cell receptors in murine autoimmune diseases. *Ann. Rev. Immunol.* 7:371–405.
4. Offner, H., M. Vainiene, D. P. Gold, B. Celnik, R. Wang, G. A. Hashim, and A. A. Vandenbark. 1992. Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats. I. T cell receptor peptide regulation of T cell clones expressing cross-reactive VS genes. *J. Immunol.* 148:1706–1711.
5. Gautman, A., C. Pearson, D. Smilek, L. Steinman, and H. McDevitt. 1992. A polyaniline peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis. *J. Exp. Med.* 176:605–609.
6. Smilek, D., D. Wraith, S. Hodgkinson, S. Dwivedy, L. Steinman, and H. McDevitt. 1991. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. *Proc. Natl. Acad. Sci. USA*. 88:9633–9637.
7. Neilson, E. G., M. J. Sun, C. J. Kelly, W. H. Hines, T. P. Haverty, M. D. Clayman, and N. E. Cooke. 1991. Molecular characterization of a major nephrito-



- genic domain in the autoantigen of anti-tubular basement membrane disease. *Proc. Natl. Acad. Sci. USA.* 88:2006–2010.
8. Adams, S., P. Leblanc, and S. Datta. 1991. Junctional region sequences of T-cell receptor  $\beta$ -chain genes expressed by pathogenic anti-DNA autoantibody-inducing helper T cells from lupus mice: Possible selection by cationic autoantigens. *Proc. Natl. Acad. Sci. USA.* 88:11271–11275.
9. Gold, D. P., M. Vainiene, B. Celnik, S. Wiley, C. Gibbs, G. A. Hashim, A. A. Vandembark, and H. Offner. 1992. Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats II. Biased T cell receptor  $V\beta$  expression predominates in spinal cord infiltrating T cells. *J. Immunol.* 148:1712–1717.
10. Gold, D., H. Offner, D. Sun, S. Wiley, A. Vandembark, and D. Wilson. 1991. Analysis of T cell receptor  $\beta$  chains in Lewis Rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3. *J. Exp. Med.* 174:1467–1476.
11. Haqqi, T., G. Anderson, S. Banerjee, and C. David. 1992. Restricted heterogeneity in T-cell antigen receptor  $V\beta$  gene usage in the lymph nodes and arthritic joints of mice. *Proc. Natl. Acad. Sci. USA.* 89:1253–1255.
12. Infante, A., H. Levcovitz, V. Gordon, K. Wall, P. Thompson, and K. Krolick. 1992. Preferential use of a T cell receptor  $V\beta$  gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice. *J. Immunol.* 148:3385–3390.
13. Paliard, X., S. G. West, J. A. Lafferty, J. R. Clements, J. W. Kappler, P. Marrack, and B. L. Kotzin. 1991. Evidence for the effects of a superantigen in rheumatoid arthritis. *Science (Wash. DC).* 253:325–329.
14. Sumida, T., F. Yonaha, T. Maeda Tanabe, E. T. Loike, H. Tomoika, and S. Yoshida. 1992. T cell receptor repertoire of infiltrating T cells in lips of Sjögren's Patients. *J. Clin. Invest.* 89:681–685.
15. Davies, T. F., A. Martin, E. S. Concepcion, P. Graves, L. Cohen, and A. Ben-Nun. 1991. Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. *N. Engl. J. Med.* 325:238–244.
16. Capra, J., and J. B. Natvig. 1993. Is there V region restriction in autoimmune diseases? *The Immunologist.* 1:1–6.
17. Clayton, J. P., G. M. Gammon, D. G. Ando, D. H. Kono, L. Hood, and E. E. Sercarz. 1989. Peptide-specific prevention of experimental allergic encephalomyelitis. *J. Exp. Med.* 169:1681–1691.
18. Urban, J. L., V. Kumar, D. H. Kono, C. Gomez, S. J. Horvath, J. Clayton, D. G. Ando, E. E. Sercarz, and L. Hood. 1988. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. *Cell.* 54:577–592.
19. Heeger, P., G. Wolf, and E. G. Neilson. 1991. The pathogenesis of tubulointerstitial nephritis. In *Nephrology*. Hatano, editors. Springer-Verlag, Tokyo. 151–164.
20. Neilson, E. G. 1989. Pathogenesis and therapy of interstitial nephritis. *Kidney Int.* 35:1257–1270.
21. Neilson, E. G., and S. M. Phillips. 1982. Murine interstitial nephritis. I. Analysis of disease susceptibility and its relationship of pleiomorphic gene products defining both immune-response genes and a restrictive requirement for cytotoxic T cells at H-2K. *J. Exp. Med.* 155:1075–1085.
22. Zakheim, B., E. McCafferty, S. M. Phillips, M. Clayman, and E. G. Neilson. 1984. Murine interstitial nephritis. II. The adoptive transfer of disease with immune T lymphocytes produces a phenotypically complex interstitial lesion. *J. Immunol.* 133:231–239.
23. Kuncio, G., E. Neilson, and T. Haverty. 1991. Mechanisms of tubulointerstitial fibrosis. *Kidney Int.* 39:550–556.
24. Haverty, T. P., C. J. Kelly, W. H. Hines, P. S. Amenta, M. Watanabe, R. A. Harper, N. A. Kefalides, and E. G. Neilson. 1988. Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. *J. Cell Biol.* 107:1359–1368.
25. Mann, R., C. J. Kelly, W. H. Hines, M. D. Clayman, N. Blanchard, M. J. Sun, and E. G. Neilson. 1987. Effector T cell differentiation in experimental interstitial nephritis. I. The development and modulation of effector lymphocyte maturation by I-J+ regulatory T cells. *J. Immunol.* 138:4200–4208.
26. Mann, R., B. Zakheim, M. Clayman, E. McCafferty, L. Michaud, and E. G. Neilson. 1985. Murine interstitial nephritis. IV. Long-term cultured L3T4+ T cell lines transfer delayed expression of disease as I-A-restricted inducers of the effector T cell repertoire. *J. Immunol.* 135:286–293.
27. Meyers, C., and C. Kelly. 1991. Effector mechanisms in organ-specific autoimmunity. I. Characterization of a CD8+ T cell line that mediates murine interstitial nephritis. *J. Clin. Invest.* 88:408–416.
28. Neilson, E. G., and S. M. Phillips. 1979. Cell-mediated immunity in interstitial nephritis. I. T lymphocyte systems in nephritic guinea pigs: the natural history and diversity of the immune response. *J. Immunol.* 123:2373–2380.
29. Neilson, E. G., E. McCafferty, S. M. Phillips, M. D. Clayman, and C. J. Kelly. 1984. Antidiotypic immunity in interstitial nephritis. II. Rats developing anti-tubular basement membrane disease fail to make an antidiotypic regulatory response: the modulatory role of an RT7.1+, OX8-suppressor T cell mechanism. *J. Exp. Med.* 159:1009–1026.
30. Clayman, M. D., H. A. Martinez, L. Michaud, R. Alper, R. Mann, N. A. Kefalides, and E. G. Neilson. 1985. Isolation and characterization of the nephritogenic antigen producing anti-tubular basement membrane disease. *J. Exp. Med.* 161:290–305.
31. Houghten, R. A. 1985. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. *Proc. Natl. Acad. Sci. USA.* 82:5131–5135.
32. Neilson, E. G., M. D. Clayman, T. Haverty, C. J. Kelly, and R. Mann. 1986. Experimental strategies for the study of cellular immunity in renal disease. *Kidney Int.* 30:264–279.
33. Rabin, H., R. Hopkins III, F. Ruscetti, R. Neubauer, R. Brown, and T. Kawakami. 1981. Spontaneous release of a factor properties of T cell growth factor from a continuous line of primate tumor T cells. *J. Immunol.* 127:1852–1856.
34. Heeger, P., G. Wolf, C. Meyers, M. J. Sun, A. Krensky, and E. G. Neilson. 1992. Isolation and characterization of cDNA from renal tubular epithelium encoding Murine Rantes, a small intercrine from the Scy superfamily. *Kidney Int.* 41:220–225.
35. Karp, S. L., T. Kieber-Emmons, M. J. Sun, G. Wolf, and E. G. Neilson. 1993. The molecular structure of a cross-reactive idiotype on autoantibodies recognizing parenchymal self. *J. Immunol.* 150:867–879.
36. Gaulton, G., S. Bangs, T. Maddock, T. Springer, D. Eardley, and T. Strom. 1985. Characterization of a monoclonal rat anti-mouse interleukin 2 receptor antibody and its use in the biochemical characterization of the murine IL-2 receptor. *Clin. Immunol. Immunopathol.* 36:18–29.
37. Ewijk, W., P. van Soest, and G. van den Engh. 1981. Fluorescence analysis and anatomic distribution of mouse T lymphocyte subsets defined by monoclonal antibodies to the antigens Thy-1, Lyt-1, Lyt-2, and T-200. *J. Immunol.* 127:2594–2604.
38. Kubo, R., W. Born, J. Kappler, P. Marrack, and M. Pigeon. 1989. Characterization of a monoclonal antibody which detects all murine  $\alpha\beta$  T cell receptors. *J. Immunol.* 142:2736–2742.
39. Okada, C., B. Holzmann, C. Guidos, E. Palmer, and I. Weissman. 1990. Characterization of a rat monoclonal antibody specific for a determinant encoded by the  $V\beta 7$  gene segment. *J. Immunol.* 144:3473–3477.
40. Pullen, A., P. Marrack, and J. Kappler. 1988. T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens. *Nature (Lond.).* 335:796–801.
41. Laio, N., J. Maltzman, and D. Raulet. 1989. Positive selection determines T cell receptor  $V\beta 14$  gene usage CD8+ T cells. *J. Exp. Med.* 170:135–143.
42. Haverty, T. P., M. Watanabe, E. G. Neilson, and C. J. Kelly. 1989. Protective modulation of class II MHC gene expression in tubular epithelium by target antigen-specific antibodies. Cell-surface directed down-regulation of transcription can influence susceptibility to murine tubulointerstitial nephritis. *J. Immunol.* 143:1133–1141.
43. Hines, W. H., R. A. Mann, C. J. Kelly, and E. G. Neilson. 1990. Murine interstitial nephritis. IX. Induction of the nephritogenic effector T cell repertoire with an antigen-specific T cell cytokine. *J. Immunol.* 144:75–83.
44. Behlke, M. A., and D. Y. Loh. 1986. Alternative splicing of murine T-cell receptor  $\beta$  chain transcripts. *Nature (Lond.).* 322:379–382.
45. Behlke, M., D. Spinella, H. Chou, W. Sha, D. Hartl, and D. Loh. 1985. T-cell receptor  $\beta$ -chain expression: Dependence on relatively few variable region genes. *Science (Wash. DC).* 229:566–570.
46. Governman, J., K. Minard, N. Shastri, T. Hunkapiller, D. Hansburg, E. Sercarz, and L. Hood. 1985. Rearranged  $\beta$  T cell receptor genes in a helper T cell clone specific for lysozyme: no correlation between  $V\beta$  an MHC restriction. *Cell.* 40:859–867.
47. Six, A., E. Jouvin-Marche, D. Loh, P. Cazenave and P. Marche. 1991. Identification of a T cell receptor  $\beta$  chain variable region,  $V\beta 20$ , that is differentially expressed in various strains of mice. *J. Exp. Med.* 174:1263–1266.
48. Rocco, M. V. and F. N. Ziyadeh. 1991. Transforming growth factor-beta: An Update on systemic and Renal Actions. In *Hormones, Autocoids, and the Kidney*. S. Goldfarb and F. N. Ziyadeh, editors. Churchill Livingstone, New York. 391–410.
49. Danska, J. S., A. M. Livingstone, V. Paragas, T. Ishihara, and C. G. Fathman. 1990. The presumptive CDR3 regions of both T cell receptor alpha and beta chains determine T cell specificity for myoglobin peptides. *J. Exp. Med.* 172:27–34.
50. Ross, A., and E. Golub. 1988. A computer graphics program system for protein structure representation. *Nucleic Acids Res.* 16:1801–1810.
51. Takahashi, H., K. B. Cease, and J. A. Berzofsky. 1989. Identification of proteases that process distinct epitopes on the same protein. *J. Immunol.* 142:2221–2229.
52. Behlke, M. A., H. S. Chou, K. Huppi, and D. Y. Loh. 1986. Murine T-cell receptor mutants with deletions of beta-chain variable region genes. *Proc. Natl. Acad. Sci. USA.* 83:767–771.
53. Siu, G., M. Kronenberg, E. Strauss, R. Haars, T. W. Mak, and L. Hood. 1984. The structure, rearrangement and expression of Dbeta gene segments of the murine T-cell antigen receptor. *Nature (Lond.).* 280:288–294.
54. Malissen, M., K. Minard, S. Mjolsness, M. Kronenberg, J. Governman, T. Hunkapiller, M. B. Prystowsky, Y. Yoshikai, F. Fitch, T. W. Mak, and L. Hood.

1984. Mouse T cell antigen receptor: structure and organization of constant and joining gene segments encoding the beta polypeptide. *Cell*. 37:1101–1110.
55. Gascoigne, N., Y. Chen, D. Becker, J. Kavalier, and M. Davis. 1984. Genomic organization and sequence of T-cell receptor  $\beta$ -chain constant- and joining-region genes. *Nature (Lond)*. 310:387–391.
56. Mossman, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. *Annu. Rev. Immunol.* 7:145–173.
57. Rudensky, A., P. Preston-Hurlburt, B. Al-Ramadi, J. Rothbard, and C. Janeway, Jr. 1992. Truncation variants of peptides isolated from MHC class II molecules suggest sequence modifs. *Nature (Lond)*. 359:429–431.
58. Sercarz, E., P. Lehman, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. *Annu. Rev. Immunol.* 11:729–766.
59. Novotny, J., S. Tonegawa, H. Saito, D. Kranz and H. Eisen. 1986. Secondary, tertiary, and quaternary structure of T-cell-specific immunoglobulin-like polypeptide chains. *Proc. Natl. Acad. Sci. USA*. 83:742–746.
60. Chothia, C., D. Boswell, and A. Lesk. 1988. Th outline structure of the T-cell  $\alpha\beta$  receptor. *EMBO (Eur. Mol. Biol. Organ.)* 7:3745–3755.
61. Jores, R., P. Alzari, and T. Meo. 1990. Resolution of hypervariable regions in T-cell receptor  $\beta$  chains by a modified Wu-Kabat index of amino acid diversity. *Proc. Natl. Acad. Sci. USA*. 87:9138–9142.
62. Jorgensen, J., P. Reay, E. Ehrlich, and M. Davis. 1992. Molecular components of T-cell recognition. *Annu. Rev. Immunol.* 10:835–873.
63. Jorgensen, J., U. Esser, B. Fazekas de St. Groth, P. Reay, and M. Davis. 1992. Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. *Nature (Lond)*. 355:224–230.
64. White, J., A. Pullen, K. Choi, P. Marrack, and J. Kappler. 1993. Antigen recognition properties of mutant  $V\beta 3+$  T cell receptors are consistent with an immunoglobulin-like structure for the receptor. *J. Exp. Med.* 177:119–125.